Dosing has begun in a Phase I/II clinical trial of BioMarin Pharmaceutical's gene therapy candidate valoctocogene roxaparvovec for patients with severe hemophilia A with pre-existing adeno-associated virus type 5 antibodies. The trial is expected to run through June 2024.
A study of 1,959 young, nulliparous, nonpregnant women in Burkina Faso, where malaria is hyperendemic, found that weekly administration of iron supplements was not associated with improved iron status, decreased anemia or increased risk of malaria, and researchers suggested re-evaluating World Health Organization guidance on supplementation. The findings were published in the Journal of Infectious Diseases.
LogicBio Therapeutics will present information on its gene editing technology for hemophilia B and methylmalonic acidemia at the American Society of Gene & Cell Therapy annual meeting. The company will discuss data from a study that tested a single injection in mouse models of hemophilia B.
A screening method for preeclampsia that includes measurement of biomarkers in addition to the mother's risk factors outperforms a standard method, which relies on medical history and maternal characteristics. "It is now time to revise the professional guidelines and to move away from using a checklist-based method for screening," said study co-author Liona Poon.
CareDx and Illumina have reached a licensing deal on Illumina's next-generation sequencing transplant clinical application products. CareDx will be the exclusive global distributor of Illumina's TruSight HLA v1 and v2 product lines and associated software, which it plans to use for diagnostic testing for bone marrow and solid organ transplantation.
Democratic Republic of Congo officials have recorded over 120 deaths for unknown reasons among internally displaced people, including 93 under the age of 15, near the nation's border with Uganda in March and April, the UN said. Anemia and fever were among the reported symptoms.
The National Institute of Allergy and Infectious Diseases is starting the first large US clinical trial to follow HIV-positive recipients of kidneys from HIV-positive donors to identify potential complications during and after surgery. The HOPE in Action Multicenter Kidney Study will involve 80 HIV-positive donors and 80 HIV-negative control donors, and the recipients will be followed for up to four years.
An experimental vaccine could be deployed by the World Health Organization in the Democratic Republic of Congo to prevent the spread of the Ebola virus. "We are very concerned and planning for all scenarios, including the worst-case scenario," WHO Deputy Secretary-General Peter Salama said.
The Peruvian health ministry announced a national epidemiological alert over reports of 19 suspected cases of Guillain-Barre syndrome, which has been tied to Zika virus infections.